The synthetic lethal interaction between the mismatch repair (MMR) protein, MLH1, and the mitochondrial base excision repair (BER), mitochondrial MMR and mtDNA replication protein, DNA polymerase γ (Pol γ) [3–5] was used in the current study for the selective treatment of MLH1 deficient cancers. The gene discussed is MLH1; the disease is cancer.